Structural, Mutagenic, and Kinetic Analysis of the Binding of Substrates and Inhibitors of Human PhenylethanolamineN-Methyltransferase

Journal of Medicinal Chemistry
2005.0

Abstract

The X-ray structure of human phenylethanolamine N-methyltransferase (hPNMT) complexed with its product, S-adenosyl-L-homocysteine (4), and the most potent inhibitor reported to date, SK&F 64139 (7), was used to identify the residues involved in inhibitor binding. Four of these residues, Val53, Lys57, Glu219 and Asp267, were replaced, in turn, with alanine. All variants had increased Km values for phenylethanolamine (10), but only D267A showed a noteworthy (20-fold) decrease in its kcat value. Both WT hPNMT and D267A had similar kcat values for a rigid analogue, anti-9-amino-6-(trifluoromethyl)benzonorbornene (12), suggesting that Asp267 plays an important role in positioning the substrate but does not participate directly in catalysis. The Ki values for the binding of inhibitors such as 7 to the E219A and D267A variants increased by 2-3 orders of magnitude. Further, the inhibitors were shown to bind up to 50-fold more tightly in the presence of S-adenosyl-L-methionine (3), suggesting that the binding of the latter brings about a conformational change in the enzyme.

Knowledge Graph

Similar Paper

Structural, Mutagenic, and Kinetic Analysis of the Binding of Substrates and Inhibitors of Human PhenylethanolamineN-Methyltransferase
Journal of Medicinal Chemistry 2005.0
Structure-Based Drug Design of Bisubstrate Inhibitors of Phenylethanolamine N-Methyltransferase Possessing Low Nanomolar Affinity at Both Substrate Binding Domains<sup>1</sup>
Journal of Medicinal Chemistry 2020.0
Molecular Recognition of Sub-micromolar Inhibitors by the Epinephrine-Synthesizing Enzyme Phenylethanolamine N-Methyltransferase
Journal of Medicinal Chemistry 2004.0
Conformational preference for the binding of biaryl substrates and inhibitors to the active site of phenylethanolamine N-methyltransferase (PNMT)
Journal of Medicinal Chemistry 1988.0
Conformational requirements of substrates for activity with phenylethanolamine N-methyltransferase
Journal of Medicinal Chemistry 1988.0
Exploring the active site of phenylethanolamine N-methyltransferase with 1,2,3,4-tetrahydrobenz[h]isoquinoline inhibitors☆
Bioorganic &amp; Medicinal Chemistry 2007.0
Conformationally defined adrenergic agents. 15. Conformationally restricted and conformationally defined tyramine analogs as inhibitors of phenylethanolamine N-methyltransferase
Journal of Medicinal Chemistry 1989.0
Comparison of the Binding of 3-Fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with Their Isosteric Sulfonamides to the Active Site of PhenylethanolamineN-Methyltransferase
Journal of Medicinal Chemistry 2006.0
Effect of Ring Size or an Additional Heteroatom on the Potency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of PhenylethanolamineN-Methyltransferase<sup>1a</sup>
Journal of Medicinal Chemistry 1996.0
Stereochemical aspects of phenylethanolamine analogs as substrates of phenylethanolamine N-methyltransferase
Journal of Medicinal Chemistry 1988.0